ORYN THERAPEUTICS, Inc.
Gary M. Phillips, MD, holds prominent leadership roles in the biopharmaceutical industry, currently serving as Chairman of the Supervisory Board at BioConnection and Nanobiotix, Chief Business Officer at ANAVEON AG, and a board member at multiple organizations including Aldeyra Therapeutics and ORYN THERAPEUTICS, LLC. With a distinguished career that includes past positions as President and CEO of OrphoMed, and Executive Vice President at Mallinckrodt Pharmaceuticals, Gary's expertise encompasses strategic management and business development in healthcare. Academic credentials include a Doctor of Medicine from the University of Pennsylvania School of Medicine, an MBA from The Wharton School, and a Bachelor of Arts in Biochemistry from the University of Pennsylvania.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
ORYN THERAPEUTICS, Inc.
Oryn Therapeutics is a clinical-stage company developing a new class of drug candidates, Orynotides. These proprietary drug candidates are engineered, stable, cyclic peptides with very low immunogenicity and toxicity. They modulate pathologic inflammation and have proven effective in animal models of autoimmune and chronic inflammatory diseases such as rheumatoid arthritis and ulcerative colitis. They have proven effective in preclinical cancer models and augment natural host defense, functioning as host-directed anti-infectives against drug resistant pathogens.